USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
JSK THERAPEUTICS, INC.
Address:
85 FORT DOUGLAS BLVD
SALT LAKE CITY, UT 84113-0000
Phone:
N/A
URL:
N/A
EIN:
126317571
DUNS:
957099869
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $119,742.00 1
SBIR Phase II $927,566.00 1

Award List:

Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$119,742.00
Agency:
HHS
Principal Investigator:
Gregory J. Johnson
Abstract:
DESCRIPTION (provided by applicant): Despite notable achievements over the past two decades, cancer remains a challenging 21st century epidemic demanding new, more effective drugs. Nitric oxide (NO) is well known to kill cancer cells without harming norma l bone marrow cells, but until now has not… More

Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$927,566.00
Agency:
HHS
Principal Investigator:
Gregory J. Johnson – 801-581-6310
Abstract:
DESCRIPTION (provided by applicant): Despite notable achievements over the past two decades, cancer remains a challenging 21st century epidemic demanding new, more effective drugs. Nitric oxide (NO) is well known to kill cancer cells without harming normal bone marrow cells, but until now has not… More